Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Disorders of Leukocytes

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...

Teratogenicity

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...

Acute Pyelonephritis I: Introduction

Acute Pyelonephritis I: Introduction

Pyelonephritis is a bacterial infection that primarily affects the renal parenchyma and collecting system, including the renal pelvis, tubules, and interstitial tissue of one or both kidneys. It can be classified as either acute—a sudden, severe infection—or chronic, which refers to long-term or recurrent kidney infections.The primary cause of acute pyelonephritis (APN) is bacterial infection, with Escherichia coli accounting for approximately 70-80% of cases. Other bacteria, such as Proteus,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

[Development of program therapy for patients with acute myeloid leukemia under the age of 60 years, based on the principles of differentiated effects].

Terapevticheskii arkhiv·2022

Same author

[Li-Fraumeni syndrome in adult patients with acute lymphoblastic leukemia].

Terapevticheskii arkhiv·2022

Same author

[Allogeneic hematopoietic stem cell transplantation in patients with multiple myeloma].

Terapevticheskii arkhiv·2022

Same author

[Multiple primary tumor of hematopoietic tissue: myeloid sarcoma in combination with mantle cell lymphoma. Case report].

Terapevticheskii arkhiv·2022

Same author

[Repeated haploidentical allogeneic hematopoietic stem cell transplantation with TCR αβ/CD19 depletion in patient with primary myelofibrosis. Case report].

Terapevticheskii arkhiv·2022

Same author

[Extracorporeal cytokine removal in chimeric antigen receptor T-cell therapy associated cytokine release syndrome in patient with acute lymphoblastic leukemia. Case report].

Terapevticheskii arkhiv·2022

Search research articles

Related Experiment Video

Updated: Jun 20, 2026

Isolation of Leukocytes from the Human Maternal-fetal Interface

Isolation of Leukocytes from the Human Maternal-fetal Interface

Published on: May 21, 2015

[Acute leukemia and pregnancy--some postulates].

Terapevticheskii Arkhiv

|August 28, 2009

Summary

Chemotherapy can cure acute leukemia in pregnant women, saving both mother and child. Children born to mothers undergoing treatment are healthy, with long-term follow-up showing no adverse effects.

Area of Science:

Hematology
Oncology
Maternal-Fetal Medicine

Context:

Acute leukemia diagnosis during pregnancy presents unique challenges for treatment and patient management.
Historically, therapeutic abortion was considered, but advancements in chemotherapy have shifted this paradigm.
Treatment is increasingly accessible, extending beyond specialized centers to regional healthcare facilities.

Purpose:

To evaluate the efficacy and safety of chemotherapy for acute leukemia in pregnant patients.
To assess the outcomes for both the mother and the neonate.
To demonstrate that preserving both lives is achievable through modern oncological interventions.

Summary:

Chemotherapy offers a viable treatment for acute leukemia in pregnant women, aiming to save both maternal and fetal lives.

More Related Videos

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Related Experiment Videos

Last Updated: Jun 20, 2026

Isolation of Leukocytes from the Human Maternal-fetal Interface

Isolation of Leukocytes from the Human Maternal-fetal Interface

Published on: May 21, 2015

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Survival rates for acute myeloid leukemia are 64%, and for acute promyelocytic leukemia (APL) and acute lymphoblastic leukemia (ALL), they are 25%.

Children born to mothers treated with chemotherapy during pregnancy have remained healthy during follow-up periods ranging from 11 months to 19 years.

Impact:

Establishes chemotherapy as a safe and effective treatment option for pregnant women with acute leukemia.
Highlights the successful management of acute leukemia, improving maternal survival and fetal outcomes.
Demonstrates the feasibility of delivering specialized cancer care in diverse clinical settings, improving access to treatment.